The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.
Zimmer Biomet modified 12 risk factors between the 2023 and 2024 filings while maintaining 15 unchanged risks, with no net additions or removals. The most significant modifications centered on reimbursement pressures and cost containment measures affecting product demand and pricing, as well as risks related to international sales and manufacturing operations. The company's risk disclosure structure remained materially consistent year-over-year, reflecting ongoing exposure to regulatory, commercial, and operational challenges without material expansion or contraction of disclosed risk categories.
Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.
🟡 Modified
If third-party payors decline to reimburse our customers for our products or reduce reimbursement levels, the demand for our products may decline and our ability to sell our products profitably may be harmed. In addition, we are subject to cost containment measures in the United States and other countries, resulting in pricing pressures, which could have a material adverse effect on our business, results of operations, and cash flows.
🔒
🟡 Modified
We conduct a significant amount of our sales and manufacturing activities outside of the U.S., which subjects us to additional business risks and may cause our profitability to decline due to increased costs.
🔒
🟡 Modified
Our restructuring programs may not be successful or we may not fully realize the expected cost savings and/or operating efficiencies from our restructuring initiatives.
🔒
🟡 Modified
Interruption of manufacturing operations could adversely affect our business, financial condition and results of operations.
🔒
🟡 Modified
We are subject to complex and expensive laws and governmental regulations relating to the development, design, product standards, packaging, advertising, promotion, post-market surveillance, manufacturing, labeling and marketing of our products, non-compliance with which could adversely affect our business, financial condition and results of operations.
🔒
🟡 Modified
We are dependent on sophisticated information technology and if we fail to effectively maintain or protect our information systems and data, including from cybersecurity events, our business could be adversely affected.
🔒
🟡 Modified
We may have additional tax liabilities as a result of examinations and audits.
🔒
🟡 Modified
Our success depends on our ability to effectively develop and market our products against those of our competitors.
🔒
🟡 Modified
Our products may become obsolete, customers may not buy our products, and our revenue and profitability may decline without the timely introduction of new products and enhancements, due to changes in markets, or due to changes in applicable standards of care.
🔒
🟡 Modified
Business and economic conditions have adversely impacted, and may, either alone or in combination with other risks, in the future adversely impact, our business, results of operations and financial condition, the nature and extent of which impacts are uncertain and unpredictable.
🔒
🟡 Modified
Changes in tax laws in countries in which we do business are expected to negatively impact our effective tax rate; further changes in tax laws may have a further negative impact.
🔒
🟡 Modified
Anti-takeover provisions in our organizational documents could delay or prevent a change of control.
🔒